Document Detail


Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
MedLine Citation:
PMID:  21318318     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature. A retrospective case series of 60 patients with recurrent WHO grade 1 meningioma treated with HU following progression after surgery and radiotherapy was conducted with primary study objective progression free survival (PFS) at 6- and 12-months. Sixty patients (45 women; 15 men: median age 61.5 years, range 26-88) with recurrent meningioma were treated with HU (1000 mg/m(2)/day orally divided twice per day; one cycle operationally defined as 4-weeks of daily HU). All patients had progressed radiographically after prior therapy with surgery (60/60) and radiotherapy (external beam radiotherapy 60/60; stereotactic radiotherapy 53/60). No patient received prior chemotherapy or targeted therapy before instituting HU. Patients received 1-12 cycles (median 2.0) of HU with modest toxicity (10% grade 3 + anemia or fatigue). There were no radiographic responses, 35% of patients had stable disease and 65% manifested progressive disease. Duration of stable disease ranged from 3 to 12 months (median 4.0 months). The overall PFS was 10% (median PFS 2.0 months). The majority of patients (80%) following progression on HU were subsequently treated on an investigational trial. In this retrospective case series, HU though generally well tolerated and convenient, appeared to have very limited activity which raises questions of what constitutes effective salvage therapy and indicates an unmet need for alternative treatments for recurrent meningiomas.
Authors:
Marc C Chamberlain; Sandra K Johnston
Related Documents :
1845848 - Etoposide in the management of non-small cell lung cancer.
21487288 - Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage ib-iiia non-sm...
2306798 - High-dose cisplatin in disseminated melanoma: a comparison of two schedules.
21258878 - Late recurrences of gastrointestinal stromal tumours (gists) after 5 years of follow-up.
7589598 - A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic col...
1786198 - Intrapleural application of recombinant interleukin-2 in patients with malignant pleuri...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-13
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  -     ISSN:  1573-7373     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Neurology and Neurological Surgery, Division of Neuro-Oncology, University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, 825 Eastlake Ave E, PO Box 19023, MS G-4940, Seattle, WA, 98109-1023, USA, chambemc@uw.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of PV signal quality using a novel circular mapping and ablation catheter versus a standa...
Next Document:  Noninvasive monitoring of tumor growth in a rat glioma model: comparison between neurological assess...